Molecular Targeted Cancer Therapies and the Kidney

Aksu O. B., EREN SADİOĞLU R., ŞENGÜL Ş.

TURKISH JOURNAL OF NEPHROLOGY, cilt.29, sa.3, ss.232-241, 2020 (ESCI) identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 29 Sayı: 3
  • Basım Tarihi: 2020
  • Doi Numarası: 10.5152/turkjnephrol.2020.4103
  • Dergi Adı: TURKISH JOURNAL OF NEPHROLOGY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.232-241
  • Anahtar Kelimeler: Cancer, CAR-T, kidney, nephrotoxicity, onconephrology, targeted therapy, CYTOKINE RELEASE SYNDROME, T-CELL THERAPY, BRAF, HYPOMAGNESEMIA, TRASTUZUMAB, TOXICITIES, CETUXIMAB, RISK
  • Ankara Üniversitesi Adresli: Evet

Özet

Novel, targeted anticancer therapies have increased survival rates in patients. However, the incidence, severity, and pattern of their toxicities are different from those of traditional chemotherapies. The high prevalence of chronic kidney disease in the general population and the increased incidence of cancer highlight the need for nephrology consultation regarding this issue. Here, we review the incidence, mechanisms, and management of adverse renal effects associated with major molecular, targeted cancer therapies. Early diagnosis and prompt intervention in case of adverse renal events are crucial for the proper management of patients with cancer treated with targeted agents.